Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Cardiac Disease

Abstract

Novel markers for cardiac disease that are both sensitive and accurate. These markers are differentially and/or specifically expressed in cardiac tissue, as opposed to other types of tissues, optionally and preferably including muscle tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of cardiac disease, including pathology and/or damage, including acute and/or chronic damage. The markers of the present invention, alone or in combination, show a high degree of differential detection between cardiac disease states and non-cardiac disease states.

1 - 25 . (canceled) 
     
     
         26 . An antibody or fragment thereof that specifically binds to an epitope in a polypeptide comprising an amino acid sequence at least 95% homologous to SEQ ID NO: 413, or a fragment thereof. 
     
     
         27 . The antibody or fragment of  claim 26 , wherein the polypeptide is selected from the group consisting of SEQ NO: 455, SEQ ID NO: 456, and SEQ ID NO: 457. 
     
     
         28 . The antibody or fragment of  claim 26 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 413 with addition of Cysteine before the first amino terminal residue of SEQ ID NO: 413. 
     
     
         29 . The antibody or fragment of  claim 26 , wherein said polypeptide consists of a sequence at least 95% homologous to SEQ ID NO: 413. 
     
     
         30 . The antibody or fragment of  claim 29 , wherein said polypeptide is selected from the group consisting of SEQ ID NO: 455, SEQ ID NO: 456, and SEQ ID NO: 457. 
     
     
         31 . The antibody or fragment of  claim 26  that specifically binds to an epitope in a polypeptide comprising the amino acid sequence of SEQ ID NO: 303. 
     
     
         32 . The antibody or fragment of  claim 26  that specifically binds to an epitope in a polypeptide consisting of the amino acid sequence of SEQ ID NO: 303. 
     
     
         33 . The antibody or fragment of  claim 26 , wherein said antibody or fragment is attached to a label. 
     
     
         34 . The antibody or fragment of  claim 26 , wherein said antibody or fragment is provided on a solid support. 
     
     
         35 . The antibody or fragment of  claim 26 , wherein said antibody is a monoclonal antibody. 
     
     
         36 . The antibody or fragment of  claim 26 , wherein said antibody is a polyclonal antibody. 
     
     
         37 . An epitope binding fragment of the antibody or fragment of  claim 26 . 
     
     
         38 . The antibody or fragment of  claim 31 , wherein said antibody is attached to a label. 
     
     
         39 . The antibody or fragment of  claim 31 , wherein said antibody is provided on a solid support. 
     
     
         40 . The antibody or fragment of  claim 31 , wherein said antibody is a monoclonal antibody. 
     
     
         41 . The antibody or fragment of  claim 31 , wherein said antibody is a polyclonal antibody. 
     
     
         42 . An epitope binding fragment of the antibody or the antigen-binding fragment of  claim 31 . 
     
     
         43 . The antibody or fragment of  claim 31 , wherein said antibody or fragment does not specifically bind to a TRIC_HUMAN protein with an amino acid sequence selected from the group consisting of SEQ ID NOs: 351 and 453. 
     
     
         44 . The antibody or fragment of  claim 26 , wherein said polypeptide comprises the sequence of SEQ ID NO: 303. 
     
     
         45 . A kit comprising the antibody or fragment of  claim 26 . 
     
     
         46 . The kit of  claim 45 , wherein said kit further comprises at least one immunoassay reagent. 
     
     
         47 . The kit of  claim 46 , wherein the immunoassay is selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA), an immunoprecipitation assay, an immunofluorescence analysis, an enzyme immunoassay (ETA), a radioimmune assay (RIA), a Western blot assay, and a slot blot assay. 
     
     
         48 . A method for detecting a disease selected from a group consisting of cardiac disease, disorder, or pathology, the method comprising
 contacting said subject or a sample from a subject with the antibody of  claim 26  under conditions that allow for the formation of a complex of antibody bound to a marker in the subject or sample,   wherein the presence of the marker indicates the subject has said disease.   
     
     
         49 . The method of  claim 48 , wherein said method comprises at least one of screening for the disease, diagnosing the disease, diagnosing the predisposition to the disease, monitoring the disease progression, monitoring treatment efficacy, monitoring relapse of the disease, or selecting a therapy for a disease. 
     
     
         50 . The method of  claim 49 , wherein the cardiac disease, disorder, or pathology is at least one of myocardial infarct, angina pectoris (stable and unstable), cardiomyopathy, myocarditis, congestive heart failure, detection of reinfarction, detection of success of thrombolytic therapy after myocardial infarct, myocardial infarct after surgery, and assessing the size of infarct in myocardial infarct.